AI CuratorAI-generated
Research summary · AI summary · not yet reviewedSubjects not reportedInterventionalTrial registry
Effects of Vancomycin on Gut Microbiome in Multiple Sclerosis
This study aims to investigate how vancomycin might affect the gut-brain axis in multiple sclerosis (MS) by examining changes in gut bacteria, immune function, and brain MRI lesions in MS patients.
- Tags
- #MSResearch
- Most relevant to
- —
- Source
- Read original source
This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
Why it matters
Understanding the role of the gut microbiome in MS could provide insights into autoimmune mechanisms and potential new approaches to manage the disease.
What this does not prove
No results are published yet, and planned enrolment and endpoints do not equal findings.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Interventional
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- Not reported
- Evidence reviewed
- Trial registry record
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
- Trial registrationVancomycin Study in Multiple Sclerosis (MS) ↗
Supporting passages (7)
study designThe study has been exempted from an IND by the FDA, since it entails the off-label use of a marketed drug."
regulatory approval detailsThe study has been exempted from an IND by the FDA, since it entails the off-label use of a marketed drug."
intervention"description": "125mg antibiotic taken 4 times daily by mouth",
comparator"description": "Matching placebo taken 4 times daily by mouth",
primary endpoint"description": "Changes in abundance of butyrate producing bacteria from baseline treatment up to 6 weeks",
findingsThe overall goal of this study is to elucidate a mechanism by which vancomycin modulates the gut-brain axis in multiple sclerosis (MS).
limitationsPlanned enrolment and endpoints are not findings.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.